循环C1QC在肿瘤中的应用:分析平台、证据缺口与临床化学转化前景
本文综述循环补体C1q C链(C1QC)作为临床化学分析物的潜力,指出传统肿瘤标志物早期诊断灵敏度与特异性有限。现有C1QC数据多源于总C1q或C1q结合活性测定及转录组、单细胞分析或小型回顾性队列,缺乏循环C1QC蛋白直接测量。综述评估了免疫分析、靶向LC-MS/MS、适配体电化学生物传感器和表面等离子共振平台的分析性能,并强调外部质量评估、前瞻性多中心验证、检测标准化及法规依从的必要性。
要点
- 传统血清肿瘤标志物早期诊断灵敏度和特异性有限,补体通路蛋白成为潜在分析物。
- 现有C1QC数据多非直接测量循环C1QC蛋白,证据存在缺口。
- C1QC临床转化需外部质量评估、前瞻性验证、检测标准化及法规合规。
核心结论
- 循环C1QC作为临床化学分析物具有转化前景,但需直接测量蛋白并完成分析性能与临床验证。
研究设计与样本
- 叙述性综述,评估C1QC的基因结构、蛋白形式异质性、翻译后修饰及多种分析平台性能。
主要发现
- 现有C1QC数据多基于组织转录组、单细胞分析、生物信息数据集或小型回顾性队列,未直接测量循环C1QC蛋白。
- 循环C1QC测量常源于总C1q或C1q结合活性测定,而非C1QC特异性方法。
- C1QC与经典补体通路激活、肿瘤相关巨噬细胞M2样极化及免疫抑制代谢重编程相关。
临床怎么用
- 临床转化前需开展外部质量评估、前瞻性多中心验证和检测标准化。
- 需考虑炎症、感染或免疫介导疾病的干扰,并遵循IVDR和FDA法规路径。
局限性
- 许多数据非直接测量循环C1QC蛋白,证据多来自转录组、单细胞分析或小型回顾性队列。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Traditional serum tumor markers, such as carcinoembryonic antigen (CEA), carbohydrate antigen 19-9 (CA 19-9), cancer antigen 125 (CA 125), α-fetoprotein (AFP), and prostate-specific antigen (PSA), exhibit limited diagnostic sensitivity and specificity during the early stages of disease and in malignancies with overlapping clinical features. This limitation has led to the investigation of complement pathway proteins as potential clinical chemistry analytes. Measurements of circulating complement C1q C chain (C1QC) are frequently derived from total C1q or C1q-binding activity assays, rather than those specific to C1QC. These measurements are linked to the activation of the classical complement pathway, M2-like polarization of tumor-associated macrophages, and immunosuppressive metabolic reprogramming. However, many of the available data are based on transcriptomic analysis of tissues, single-cell analysis, bioinformatic datasets, or small retrospective cohorts without directly measuring the C1QC protein in the circulation. This narrative review critically evaluates C1QC within the clinical chemistry framework, covering its gene structure, proteoform heterogeneity, and post-translational modifications. This study also evaluated the analytical performance metrics of immunoassays, targeted liquid chromatography-tandem mass spectrometry (LC-MS/MS), aptamer-based electrochemical biosensors, and surface plasmon resonance platforms. It critically appraises the reported diagnostic and prognostic associations, including the proposed incremental contributions of multimarker panels. Additionally, external quality assessment, prospective multicenter validation, assay harmonization, and consideration of interference from inflammatory, infectious, or immune-mediated conditions are required for this approach. Compliance with the In Vitro Diagnostic Medical Devices Regulation (IVDR) and United States Food and Drug Administration (FDA) regulatory pathways is also necessary.
引用
- Abu Zeid IM, Afzal M, Rafeeq M, et al. Circulating C1QC in cancer: analytical platforms, evidence gaps, and prospects for clinical chemistry translation. Clin Chim Acta. 2026. PMID: 42336257. doi:10.1016/j.cca.2026.121198
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。